Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III Allergan and partner Molecular Partners say a pair of two studies of abicipar show that the drug is non-inferior to monthly dosing with Roche and Novartis’ blockbuster Lucentis (ranibizumab) when ... The new drug could halve the number of injections

Regeneron’s Dupixent and Praluent falls short

Regeneron’s Dupixent and Praluent falls short momentum. Eylea is already fending off pressure from Novartis’ Lucentis (ranibizumab) but faces more competition in the market from late-stage experimental drugs such as Novartis’ RTH258, as well as biosimilars ... of Lucentis.

The good, the bad and the ugly

The good, the bad and the ugly It hopes these measures will help offset Lucentis’ EU patent expiry in 2022.”. ... Regeneron remains the leading player, with 10% growth in 2017 thanks to superior data for Eylea against Lucentis.

It’s only money

It’s only money problem breached European Union competition rules - this ruling upheld a 2014 decision by Italy’s antitrust authority that the drugmakers colluded to boost sales of Lucentis by discrediting the cheaper Avastin

Regeneron and Bayer drop AMD combination

Regeneron and Bayer drop AMD combination Novartis does have to be wary of cannibalising sales of its established AMD therapy Lucentis (ranibizumab), which is playing second fiddle to Eylea but is still a blockbuster – albeit one headed

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...